Parham, David M <br/><br/>
The impact of human epidermal growth factor receptor 2 neoadjuvant monoclonal antibody (trastuzumab) therapy in ductal carcinoma in situ of the breast.  [electronic resource] 

 -  Histopathology  05 2017 
 - 1009-1011 p.  digital 
<br/><br/> Publication Type: Letter 
<br/><br/><label>ISSN: </label>1365-2559 
<br/><br/><label>Standard No.: </label>10.1111/his.13145  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents, Immunological--therapeutic use<br/>Breast Neoplasms--drug therapy<br/>Carcinoma, Intraductal, Noninfiltrating--drug therapy<br/>Chemotherapy, Adjuvant--methods<br/>Female<br/>Humans<br/>Middle Aged<br/>Neoadjuvant Therapy--methods<br/>Receptor, ErbB-2--immunology<br/>Retrospective Studies<br/>Trastuzumab--therapeutic use<br/>Treatment Outcome